Biopharma firm SinoMab BioScience seeks $1.75b in IPO

It is focused on the treatment of immunological diseases, with a focus on mAb-based biologics.

Hong Kong-based biopharmaceutical company SinoMab BioScience is seeking to list in the mainboard of the Stock Exchange of Hong Kong, an announcement revealed.

SinoMab BioScience plans to offer an aggregate of more than 182 million offer shares, consisting of 168.9 million international offer shares and 18.2 million Hong Kong offer shares at a price range between $7.6-$9.6 per share.

Yunnan Baiyao Group and Reach Software Hong Kong were announced as the cornerstone investors of the company.

SinoMab BioScience is a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, with a primary focus on mAb-based biologics.

China International Capital Corporation Hong Kong Securities Limited and Orient Capital Hong Kong were the joint sponsors of the listing; CICC and Orient Securities Hong Kong are appointed as the joint global coordinators, joint bookrunners and joint lead managers; whilst China Everbright Securities, Guotai Junan Securities, CMB International Capital, Haitong International Securities Company, Fosun Hani Securities and Victory Securities Company are the joint bookrunners and joint lead managers.

The public offering opened on 9AM on Thursday, 31 October and will close at 12NN on Tuesday, 5 November, in Hong Kong.

Dealings in shares on bourse are expected to commence at 9AM on 12 November, with the stock code 3681.HK in board lots of 300 shares each.